Agog Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Agog Pharma Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $5.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Agog Pharma Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $5.0M Trade | TransData Nexus

Agog Pharma Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $5.0M Total Trade · DGFT Verified

Agog Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $5.0M across 6 products in 6 therapeutic categories. Based on 211 verified export shipments from Indian Customs (DGFT) records, Agog Pharma Limited is the #1 Indian exporter in 1 product including Nystatin. Top exports include Metronidazole ($2.4M), Nystatin ($1.4M), Griseofulvin ($728.8K).

Agog Pharma Limited — Export Portfolio & Destination Treemap

Agog Pharma Limited pharmaceutical export portfolio — 6 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Agog Pharma Limited? — Company Overview & Market Position

Agog Pharma Limited, established on December 20, 1990, is a public limited company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH1990PLC059515. It operates in the pharmaceutical sector, specializing in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The authorized and paid-up capital of Agog Pharma Limited is ₹3.15 crore.

As of January 10, 2026, Agog Pharma Limited employs 88 professionals. The company's leadership comprises three directors: Aziz Abdulhamid Damani, appointed on June 20, 2005; Shenaz Aziz Damani, appointed on June 2, 2006; and Anil Kumar Anirudh Pandey, appointed on September 30, 2005.

What Does Agog Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metronidazole$2.4M 2Nystatin$1.4M

Product Portfolio — Top 6 by Export Value

Agog Pharma Limited exports 6 pharmaceutical products across 6 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metronidazole	Advanced Antibiotics	$2.4M	85	1.2%	12
2	Nystatin	Antifungals	$1.4M	29	2.8%	1
3	Griseofulvin	Advanced Antifungals	$728.8K	50	2.0%	6
4	Quinine	Antimalarial & Antiparasitic	$258.7K	29	1.3%	11
5	Captopril	Cardiovascular	$93.5K	10	0.8%	10
6	Aminophylline	Respiratory & OTC	$39.9K	8	0.7%	12

Agog Pharma Limited exports 6 pharmaceutical products across 6 therapeutic categories with a total export value of $5.0M. The company is the #1 Indian exporter in 1 product: Nystatin. The top category is Advanced Antibiotics (48.5% of portfolio), followed by Antifungals (29.0%), indicating a concentrated portfolio with the top 5 products accounting for 99.2% of total export value.

Agog Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Agog Pharma Limited operates its manufacturing facility in Vasai, Mumbai, Maharashtra. The plant specializes in the production of various pharmaceutical dosage forms, including tablets, liquid orals, capsules, and dry syrup formulations. The facility is certified by WHO-GMP and ISO 9001:2000, ensuring adherence to international quality standards.

3Key Leadership

The leadership team at Agog Pharma Limited includes:

Aziz Abdulhamid Damani: Director since June 20, 2005.

Shenaz Aziz Damani: Director since June 2, 2006.

Anil Kumar Anirudh Pandey: Whole-Time Director since September 30, 2005.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Agog Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Agog Pharma Limited's export data indicates a significant presence in regulated markets, with a total export value of $5.0 million USD across 211 shipments. The company's top five exported products include Nystatin, Griseofulvin, Metronidazole, Quinine, and Captopril, with Nystatin leading as the top product. This suggests that Agog Pharma Limited has established a foothold in markets that require stringent regulatory compliance, such as the United States, European Union, United Kingdom, Australia, and Japan. However, specific regulatory filings, approvals, and market access statuses in these regions are not detailed in the available data.

2Emerging Markets

Agog Pharma Limited's export data highlights a strong presence in emerging markets, with significant exports to regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO-GMP standards and ISO 9001:2000 certification facilitates access to these markets, as these certifications are often prerequisites for entry. The company's portfolio concentration, with the top five products accounting for 99.2% of exports, indicates a focused strategy that may enhance its competitiveness in these regions.

3Geographic Strategy

Agog Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Agog Pharma Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided data. However, the company's export data indicates a significant presence in markets that require stringent regulatory compliance, suggesting that Agog Pharma Limited may have engaged in the necessary regulatory processes to access these markets.

2WHO & EU GMP

Agog Pharma Limited's manufacturing facility is certified by WHO-GMP and ISO 9001:2000, indicating compliance with international quality standards. While specific EU GMP certificates and EDQM status are not detailed in the available data, the company's adherence to WHO-GMP standards suggests a commitment to quality that aligns with EU GMP requirements.

3CDSCO & Indian Regulatory

Specific details regarding Agog Pharma Limited's CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not available in the provided data. However, the company's compliance with WHO-GMP and ISO 9001:2000 standards suggests adherence to Indian regulatory requirements.

Agog Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Agog Pharma Limited operates in a competitive pharmaceutical industry, with its top five products accounting for 99.2% of its export value. The company's focus on specific therapeutic categories, such as Advanced Antibiotics, Antifungals, and Advanced Antifungals, positions it against other manufacturers in these segments. While specific market share comparisons and head-to-head analyses are not available in the provided data, Agog Pharma Limited's adherence to international quality standards and its diversified geographic strategy may enhance its competitive position.

2Key Differentiators

Agog Pharma Limited's key differentiators include its adherence to international quality standards, as evidenced by its WHO-GMP and ISO 9001:2000 certifications, and its diversified geographic strategy targeting both regulated and emerging markets. The company's focused product portfolio, with the top five products accounting for 99.2% of exports, indicates a strategic emphasis on specific therapeutic categories, potentially enhancing its expertise and market presence in these segments.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Agog Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Agog Pharma Limited demonstrates a strong track record in the pharmaceutical industry, with a significant export value of $5.0 million USD across 211 shipments. The company's adherence to international quality standards, as evidenced by its WHO-GMP and ISO 9001:2000 certifications, indicates reliability and a commitment to quality. The focused product portfolio, with the top five products accounting for 99.2% of exports, suggests consistency in its offerings. However, specific indicators of reliability, such as customer feedback or supply chain performance metrics, are not available in the provided data.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm the FDA approval status of specific products by checking the FDA's official website or contacting Agog Pharma Limited directly.

WHO-GMP Certification: Verify the WHO-GMP certification by consulting the World Health Organization's official website or Agog Pharma Limited's certification documents.

Frequently Asked Questions — Agog Pharma Limited

How many pharmaceutical products does Agog Pharma Limited export from India?

Agog Pharma Limited exports 6 pharmaceutical products across 6 therapeutic categories. The top exports are Metronidazole ($2.4M), Nystatin ($1.4M), Griseofulvin ($728.8K), Quinine ($258.7K), Captopril ($93.5K). Total export value is $5.0M.

What is Agog Pharma Limited's total pharmaceutical export value?

Agog Pharma Limited's total pharmaceutical export value is $5.0M, based on 211 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Agog Pharma Limited the #1 Indian exporter?

Agog Pharma Limited is the #1 Indian exporter in 1 products: Nystatin (2.8% market share).

What therapeutic categories does Agog Pharma Limited cover?

Agog Pharma Limited exports across 6 therapeutic categories. The largest are Advanced Antibiotics (48.5%, 1 products), Antifungals (29.0%, 1 products), Advanced Antifungals (14.6%, 1 products).

Get Full Agog Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.